The deficiency of C1 inhibitor and its treatment

Immunobiology

Volumn 212, Issue 4-5, 2007, Pages 325-331

  Cicardi, Marco ^a   Zingale, Lorenza C ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

C1 inhibitor; Danazol; Dx 88; Hereditary angioedema; Icatibant; Tranexamic acid

Indexed keywords

4 AMINOMETHYLBENZOIC ACID; AMINOCAPROIC ACID; ANDROGEN; ANTIFIBRINOLYTIC AGENT; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONIST; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; DX 88; ECALLANTIDE; FRESH FROZEN PLASMA; ICATIBANT; KALLIKREIN; KALLIKREIN INHIBITOR; METHYLTESTOSTERONE; NEW DRUG; PLACEBO; PLASMIN; RECOMBINANT COMPLEMENT COMPONENT C1S INHIBITOR; RECOMBINANT PROTEIN; STANOZOLOL; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG MONITORING; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; FLUSHING; GENETIC CODE; HUMAN; IMMUNOPATHOGENESIS; LIVER CANCER; LONG TERM CARE; NAUSEA; NONHUMAN; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN SECRETION; REPEATED DRUG DOSE; RHINITIS; SIDE EFFECT; SINGLE DRUG DOSE; SYMPTOM;

EID: 34249713738     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2007.04.003     Document Type: Article

References (72)

1. Agostoni A., Cicardi M., Martignoni G.C., Bergamaschini L., and Marasini B. Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema. J. Allergy Clin. Immunol. 65 (1980) 75-79
2. Agostoni A., Bergamaschini L., Martignoni G., Cicardi M., and Marasini B. Treatment of acute attacks of hereditary angioedema with C1-inhibitor concentrate. Ann. Allergy 44 (1980) 299-301
3. Agostoni A., Aygoren-Pursun E., Binkley K.E., Blanch A., Bork K., Bouillet L., Bucher C., Castaldo A.J., Cicardi M., Davis A.E., De Carolis C., Drouet C., Duponchel C., Farkas H., Fay K., Fekete B., Fischer B., Fontana L., Fust G., Giacomelli R., Groner A., Erik Hack C., Harmat G., Jakenfelds J., Juers M., Kalmar L., Kaposi P.N., Karadi I., Kitzinger A., Kollar T., Kreuz W., Lakatos P., Longhurst H.J., Lopez-Trascasa M., Martinez-Saguer I., Monnier N., Nagy I., Nemeth E., Nielsen E.W., Nuijens J.H., O'Grady C., Pappalardo E., Penna V., Perricone C., Perricone R., Rauch U., Roche O., Rusicke E., Spath P.J., Szendei G., Takacs E., Tordai A., Truedsson L., Varga L., Visy B., Williams K., Zanichelli A., and Zingale L. Hereditary and acquired angioedema: Problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J. Allergy Clin. Immunol. 114 (2004) S51-S131
4. Akbary A.M., Wirth K.J., and Scholkens B.A. Efficacy and tolerability of Icatibant (Hoe 140) in patients with moderately severe chronic bronchial asthma. Immunopharmacology 33 (1996) 238-242
5. Anonymous. Icatibant: HOE 140, JE 049, JE049. Drugs R. D. 5 (2004) 343-348
6. Anonymous. Icatibant: HOE 140, JE 049, JE049. Drugs R. D. 6 (2005) 239-244
7. Bergamaschini L., and Cicardi M. Recent advances in the use of C1 inhibitor as a therapeutic agent. Mol. Immunol. 40 (2003) 155-158
8. Blohme G. Treatment of hereditary angioneurotic oedema with tranexamic acid. A random double-blind cross-over study. Acta Med. Scand. 192 (1972) 293-298
9. Bork K., and Barnstedt S.E. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch. Intern. Med. 161 (2001) 714-718
10. Bork K., and Schneiders V. Danazol-induced hepatocellular adenoma in patients with hereditary angio-oedema. J. Hepatol. 36 (2002) 707-709
11. Bork, K., Frank, J., Kreuz, W., Dong, L., Rosenkranz, B., Knolle, J., 2005. Novel approach to treatment of hereditary angioedema with Icatibant, a bradykinin receptor antagonist. In: IV C1 Inhibitor Deficiency Workshop, Budapest 29 April-1 May Abstract Book, 19.
12. Bos I.G., Hack C.E., and Abrahams J.P. Structural and functional aspects of C1-inhibitor. Immunobiology 205 (2002) 518-533
13. Bowen T., Cicardi M., Farkas H., Bork K., Kreuz W., Zingale L., Varga L., Martinez-Saguer I., Aygoren-Pursun E., Binkley K., Zuraw B., Davis A., Hebert J., Ritchie B., Burnham J., Castaldo A., Menendez A., Nagy I., Harmat G., Bucher C., Lacuesta G., Issekutz A., Warrington R., Yang W., Dean J., Kanani A., Stark D., McCusker C., Wagner E., Rivard G.E., Leith E., Tsai E., Macsween M., Lyanga J., Serushago B., Leznoff A., Waserman S., and De Serres J. Canadian 2003 international consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema. J. Allergy Clin. Immunol. 114 (2004) 629-637
14. Caballero T., and Lopez-Serrano C. Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema. J. Allergy Clin. Immunol. 117 (2006) 476-477
15. Caliezi C., Zeerleder S., Redondo M., Regli B., Rothen H.U., Zurcher-Zenklusen R., Rieben R., Devay J., Hack C.E., Lammle B., and Wuillemin W.A. C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction. Crit. Care Med. 30 (2002) 1722-1728
16. Cicardi M., Bergamaschini L., Marasini B., Boccassini G., Tucci A., and Agostoni A. Hereditary angioedema: an appraisal of 104 cases. Am. J. Med. Sci. 284 (1982) 2-9
17. Cicardi M., Bergamaschini L., Tucci A., Agostoni A., Tornaghi G., Coggi G., Colombi R., and Viale G. Morphologic evaluation of the liver in hereditary angioedema patients on long-term treatment with androgen derivatives. J. Allergy Clin. Immunol. 72 (1983) 294-298
18. Cicardi M., Bergamaschini L., Cugno M., Hack E., Agostoni G., and Agostoni A. Long-term treatment of hereditary angioedema with attenuated androgens: a survey of a 13-year experience. J. Allergy Clin. Immunol. 87 (1991) 768-773
19. Cicardi M., Mannucci P.M., Castelli R., Rumi M.G., and Agostoni A. Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of C1-inhibitor concentrate. Transfusion 35 (1995) 209-212
20. Cicardi M., Castelli R., Zingale L.C., and Agostoni A. Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J. Allergy Clin. Immunol. 99 (1997) 194-196
21. Cicardi M., Zingale L., Zanichelli A., Pappalardo E., and Cicardi B. C1 inhibitor: molecular and clinical aspects. Springer Semin. Immunopathol. 27 (2005) 286-298
22. Crampon D., Barnoud R., Durand M., Ponard D., Jacquot C., Sotto J.J., Letoublon C., and Zarski J.P. Danazol therapy: an unusual aetiology of hepatocellular carcinoma. J. Hepatol. 29 (1998) 1035-1036
23. Cugno M., Cicardi M., and Agostoni A. Activation of the contact system and fibrinolysis in autoimmune acquired angioedema: a rationale for prophylactic use of tranexamic acid. J. Allergy Clin. Immunol. 93 (1994) 870-876
24. Cullmann W., Kovary P.M., Muller N., and Dick W. Complement, coagulation and fibrinolytic parameters in hereditary angioedema (HAE). Clin. Exp. Immunol. 49 (1982) 618-622
25. Curd J.G., Prograis Jr. L.J., and Cochrane C.G. Detection of active kallikrein in induced blister fluids of hereditary angioedema patients. J. Exp. Med. 152 (1980) 742-747
26. Davis III A.E. The pathogenesis of hereditary angioedema. Transfus. Apheresis Sci. 29 (2003) 195-203
27. Davis III A.E. Biological effects of C1 inhibitor. Drug News Perspect. 17 (2004) 439-446
28. Davis III A.E. The pathophysiology of hereditary angioedema. Clin. Immunol. 114 (2005) 3-9
29. De Serres J., Groner A., and Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert((R)) P) in hereditary angioedema: a review. Transfus. Apheresis Sci. 29 (2003) 247-254
30. Donaldson V.H. Mechanisms of activation of C'1 esterase in hereditary angioneurotic edema plasma in vitro. J. Exp. Med. 127 (1968) 411-429
31. Donaldson V.H. Kinin formation in hereditary angioneurotic edema (HANE) plasma. Int. Arch. Allergy Appl. Immunol. 45 (1973) 206-209
32. Donaldson V.H., and Rosen F.S. Action of complement in hereditary angioneurotic edema: the role of C'1-esterase. J. Clin. Invest. 43 (1964) 2204-2213
33. Donaldson V.H., Ratnoff O.D., Dias Da Silva W., and Rosen F.S. Permeability-increasing activity in hereditary angioneurotic edema plasma. II. Mechanism of formation and partial characterization. J. Clin. Invest. 48 (1969) 642-653
34. Donaldson V.H., Rosen F.S., and Bing D.H. Role of the second component of complement (C2) and plasmin in kinin release in hereditary angioneurotic edema (H.A.N.E.) plasma. Trans. Assoc. Am. Physicians 90 (1977) 174-183
35. Fields T., Ghebrehiwet B., and Kaplan A.P. Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of "spontaneous" formation of bradykinin. J. Allergy Clin. Immunol. 72 (1983) 54-60
36. Frank M.M., Sergent J.S., Kane M.A., and Alling D.W. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N. Engl. J. Med. 286 (1972) 808
37. Frank M.M., Gelfand J.A., and Atkinson J.P. Hereditary angioedema: the clinical syndrome and its management. Ann. Intern. Med. 84 (1976) 580-593
38. Frank M.M. Hereditary angioedema: a half century of progress. J. Allergy Clin. Immunol. 114 (2004) 626-628
39. Frank M.M. Hereditary angioedema: the rewards of studying a rare disease. Curr. Allergy Asthma Rep. 4 (2004) 251-253
40. Gadek J.E., Hosea S.W., Gelfand J.A., Santaella M., Wickerhauser M., Triantaphyllopoulos D.C., and Frank M.M. Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. N. Engl. J. Med. 302 (1980) 542-546
41. Gelfand J.A., Sherins R.J., Alling D.W., and Frank M.M. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N. Engl. J. Med. 295 (1976) 1444-1448
42. Gompels M.M., and Lock R.J. C1 inhibitor deficiency: diagnosis. Clin. Exp. Dermatol. 30 (2005) 460-462
43. Gonzales-Quevedo T., Caballero T., Cicardi M., Bork K., and Williams A. The synthetic Kunitz domain protein Dx88 to treat angioedema in patients with hereditary angioedema. Int. Immunopharmacol. 2 (2002) 1318
44. Han E.D., MacFarlane R.C., Mulligan A.N., Scafidi J., and Davis III A.E. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J. Clin. Invest. 109 (2002) 1057-1063
45. Hill B.J., Thomas S.H., and McCabe C. Fresh frozen plasma for acute exacerbations of hereditary angioedema. Am. J. Emerg. Med. 22 (2004) 633
46. Kaplan A.P., Joseph K., and Silverberg M. Pathways for bradykinin formation and inflammatory disease. J. Allergy Clin. Immunol. 109 (2002) 195-209
47. Kleniewski J., Blankenship D.T., Cardin A.D., and Donaldson V. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin. J. Lab. Clin. Med. 120 (1992) 129-139
48. Kunschak M., Engl W., Maritsch F., Rosen F.S., Eder G., Zerlauth G., and Schwarz H.P. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion 38 (1998) 540-549
49. Lehmann A. Ecallantide (Dyax/Genzyme). Curr. Opin. Invest. Drugs 7 (2006) 282-290
50. Lumry W., Ritchie B., Beck T., and Morrison J. Interim results of EDEMA2, a multicenter, open-label, repeat-dosing study of intravenous and subcutaneous administration of ecallantide (DX-88) in hereditary angioedema. J. Allergy Clin. Immunol. 117 (2006) S179
51. Lundh B., Laurell A.B., Wetterqvist H., White T., and Granerus G. A case of hereditary angioneurotic oedema, successfully treated with epsilon-aminocaproic acid. Studies on C'1 esterase inhibitor, C'1 activation, plasminogen level and histamine metabolism. Clin. Exp. Immunol. 3 (1968) 733-745
52. Marasini B., Cicardi M., Martignoni G.C., and Agostoni A. Treatment of hereditary angioedema. Klin. Wochenschr. 56 (1978) 819-823
53. Nilsson I.M., Andersson L., and Bjorkman S.E. Epsilon-aminocaproic acid (E-ACA) as a therapeutic agent based on 5 year's clinical experience. Acta Med. Scand. Suppl. 448 (1966) 1-46
54. Nuijens J., Verdonk R., Van Doorn M., Burggraaf K., Cohen A., Choi G., Soeters M., Hack C.E., Levi M., Sisk E., and Pinciaro P. Clinical studies of recombinant human C1 inhibitor in subjects with hereditary angioedema. J. Allergy Clin. Immunol. 115 (2005) S202
55. Nussberger J., Cugno M., Amstutz C., Cicardi M., Pellacani A., and Agostoni A. Plasma bradykinin in angio-oedema. Lancet 351 (1998) 1693-1697
56. Pappalardo E., Zingale L.C., and Cicardi M. Increased expression of C1-inhibitor mRNA in patients with hereditary angioedema treated with Danazol. Immunol. Lett. 86 (2003) 271-276
57. Pickering R.J., Good R.A., Kelly J.R., and Gewurz H. Replacement therapy in hereditary angioedema. Successful treatment of two patients with fresh frozen plasma. Lancet 1 (1969) 326-330
58. Rosen F.S., and Davis III A.E. Deficiencies of C1 inhibitor. Best Pract. Res. Clin. Gastroenterol. 19 (2005) 251-261
59. Schapira M., Silver L.D., Scott C.F., Schmaier A.H., Prograis Jr. L.J., Curd J.G., and Colman R.W. Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N. Engl. J. Med. 308 (1983) 1050-1053
60. Sheffer A.L., Fearon D.T., and Austen K.F. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. J. Allergy Clin. Immunol. 68 (1981) 181-187
61. Sheffer A.L., Fearon D.T., and Austen K.F. Hereditary angioedema: a decade of management with stanozolol. J. Allergy Clin. Immunol. 80 (1987) 855-860
62. Spaulding W.B. Methyltestosterone therapy for hereditary episodic edema (hereditary angioneurotic edema). Ann. Intern. Med. 53 (1960) 739-745
63. Szeplaki G., Varga L., Valentin S., Kleiber M., Karadi I., Romics L., Fust G., and Farkas H. Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema. J. Allergy Clin. Immunol. 115 (2005) 864-869
64. Turner P., Dear J., Scadding G., and Foreman J.C. Role of kinins in seasonal allergic rhinitis: icatibant, a bradykinin B2 receptor antagonist, abolishes the hyperresponsiveness and nasal eosinophilia induced by antigen. J. Allergy Clin. Immunol. 107 (2001) 105-113
65. van Doorn M.B., Burggraaf J., van Dam T., Eerenberg A., Levi M., Hack C.E., Schoemaker R.C., Cohen A.F., and Nuijens J. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J. Allergy Clin. Immunol. 116 (2005) 876-883
66. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 29 (1985) 236-261
67. Vogelaar E.F., Brummelhuis H.G., and Krijnen H.W. Contributions to the optimal use of human blood. 3. Large-scale preparation of human c1 esterase inhibitor concentrate for clinical use. Vox Sang 26 (1974) 118-127
68. Waytes A.T., Rosen F.S., and Frank M.M. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N. Engl. J. Med. 334 (1996) 1630-1634
69. Williams A., and Baird L.G. DX-88 and HAE: a developmental perspective. Transfus. Apheresis Sci. 29 (2003) 255-258
70. Williams T. DX-88, a novel recombinant protein inhibitor of plasma kallikrein: safety and immunogenicity in early studies. J. Allergy Clin. Immunol. 115 (2005) S181
71. Zingale L.C., Pappalardo E., Zanichelli A., Agostoni A., and Cicardi M. C1 inhibitor concentrate: efficacy and adverse reactions. Int. Immunopharmacol. 318 (2002) 1385
72. Zuraw B.L. Current and future therapy for hereditary angioedema. Clin. Immunol. 114 (2005) 10-16